Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTX NASDAQ:BIOR NASDAQ:GTBP NASDAQ:PWUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$0.37-13.4%$0.92$0.34▼$297.50$1.73M1.481.50 million shs1.79 million shsBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.10$660K1.1286,634 shs16,292 shsGTBPGT Biopharma$0.69+1.3%$0.95$0.55▼$4.10$2.46M1.32702,318 shs282,895 shsPWUPPowerUp Acquisition$0.34+0.5%$0.43$8.05▼$15.80$2.67M0.053,464 shs2.67 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-17.24%-39.66%-59.61%-63.79%-99.85%BIORBiora Therapeutics0.00%0.00%0.00%0.00%-97.53%GTBPGT Biopharma-7.02%-9.20%-17.33%-66.89%-66.07%PWUPPowerUp Acquisition+8.48%-4.23%-16.48%-3.37%-97.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$0.37-13.4%$0.92$0.34▼$297.50$1.73M1.481.50 million shs1.79 million shsBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.10$660K1.1286,634 shs16,292 shsGTBPGT Biopharma$0.69+1.3%$0.95$0.55▼$4.10$2.46M1.32702,318 shs282,895 shsPWUPPowerUp Acquisition$0.34+0.5%$0.43$8.05▼$15.80$2.67M0.053,464 shs2.67 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-17.24%-39.66%-59.61%-63.79%-99.85%BIORBiora Therapeutics0.00%0.00%0.00%0.00%-97.53%GTBPGT Biopharma-7.02%-9.20%-17.33%-66.89%-66.07%PWUPPowerUp Acquisition+8.48%-4.23%-16.48%-3.37%-97.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 1.00SellN/AN/ABIORBiora Therapeutics 3.00Buy$23.0015,664.22% UpsideGTBPGT Biopharma 2.67Moderate Buy$11.001,491.90% UpsidePWUPPowerUp Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIOR, GTBP, ADTX, and PWUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ADTXAditxtWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025GTBPGT BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ADTXAditxtWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (E+)9/27/2025GTBPGT BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$130K13.98N/AN/A($1.52) per share-0.24BIORBiora Therapeutics$892K0.74N/AN/A($36.43) per share0.00GTBPGT BiopharmaN/AN/AN/AN/A($0.75) per shareN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$34.45MN/A0.00∞N/A-206,431.38%-316.98%-80.88%11/17/2025 (Estimated)BIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/AGTBPGT Biopharma-$13.16M-$4.07N/AN/AN/AN/A-1,804.34%-200.12%11/13/2025 (Estimated)PWUPPowerUp AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest BIOR, GTBP, ADTX, and PWUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025GTBPGT Biopharma-$0.38N/AN/AN/AN/AN/A8/14/2025Q2 2025ADTXAditxtN/A-$3.45N/A-$3.45N/AN/A8/14/2025Q2 2025GTBPGT Biopharma-$0.68-$0.55+$0.13-$0.55N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ABIORBiora TherapeuticsN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/APWUPPowerUp AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.020.02BIORBiora TherapeuticsN/A0.050.05GTBPGT BiopharmaN/A2.762.76PWUPPowerUp AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%BIORBiora Therapeutics43.74%GTBPGT Biopharma8.15%PWUPPowerUp Acquisition19.17%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%BIORBiora Therapeutics51.08%GTBPGT Biopharma3.40%PWUPPowerUp Acquisition48.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt604.98 million4.98 millionNo DataBIORBiora Therapeutics1204.52 million2.21 millionOptionableGTBPGT Biopharma83.56 million3.44 millionNo DataPWUPPowerUp AcquisitionN/A7.77 million4.04 millionNot OptionableBIOR, GTBP, ADTX, and PWUP HeadlinesRecent News About These CompaniesPowerUp Acquisition (NASDAQ:PWUP) Stock Price Down 4% - Here's What HappenedOctober 16 at 2:35 AM | americanbankingnews.comAspire Biopharma, Inc.: Aspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | finanznachrichten.deAspire Biopharma, PowerUp Acquisition complete business combinationFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma announces public listing on NasdaqFebruary 20, 2025 | markets.businessinsider.comAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 20, 2025 | accessnewswire.comAAspire Biopharma Holdings, Inc., Announces Public Listing on NasdaqFebruary 19, 2025 | accessnewswire.comA(PWUP) Technical Pivots with Risk ControlsFebruary 13, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp trading resumesFebruary 12, 2025 | markets.businessinsider.comPowerUp Acquisition Corp trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPowerUp Stock Soars to All-Time High of $14.84 Amidst Strong GrowthFebruary 11, 2025 | msn.comPowerUp Acquisition Corp. Approves Merger with Aspire BiopharmaFebruary 11, 2025 | msn.comWhen (PWUP) Moves Investors should ListenFebruary 2, 2025 | news.stocktradersdaily.comNPowerUp Acquisition Corp. Cl AJanuary 17, 2025 | wsj.comHow to Take Advantage of moves in (PWUP)January 12, 2025 | news.stocktradersdaily.comNPWUP PowerUp Acquisition Corp.December 12, 2024 | seekingalpha.comHow To Trade (PWUP)November 19, 2024 | news.stocktradersdaily.comNWhen the Price of (PWUP) Talks, People ListenOctober 18, 2024 | news.stocktradersdaily.comNSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP and ESGROctober 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, PWUP, RVNC, ESGR on Behalf of ShareholdersOctober 8, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of PWUP, ESGROctober 7, 2024 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOR, GTBP, ADTX, and PWUP Company DescriptionsAditxt NASDAQ:ADTX$0.36 -0.06 (-13.43%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Biora Therapeutics NASDAQ:BIORBiora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.GT Biopharma NASDAQ:GTBP$0.69 +0.01 (+1.32%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.PowerUp Acquisition NASDAQ:PWUP$0.34 +0.00 (+0.53%) As of 10/15/2025PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Intel's Turnaround Hits Hyperspeed With A New 52-Week High Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Energy Crunch Ahead: 3 Natural Gas Stocks Set to Gain Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
